Axogen has delivered a very large 3 year return, which puts a bright spotlight on what investors are really paying for in terms of future cash generation. With the share price recently closing at US$58.63, the question now is how that move lines up with the cash flows the business may realistically produce over time. The stock has returned roughly 9x over the past 3 years, which makes the link between Axogen's current valuation and its cash flow profile especially important for anyone...
Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next...
Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Motley Fool Press Release.
Detailed price information for Axogen Inc (AXGN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Biohaven Ltd (BHVN-N) from The Globe and Mail including charting and trades.
Axogen (AXGN) has an average rating of buy and mean price target of $53.70, according to analysts po
Detailed price information for Axogen Inc (AXGN-Q) from The Globe and Mail including charting and trades.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Detailed price information for Axogen Inc (AXGN-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.
Through its BioCircuit buyout, Axogen hopes to extend the market uptake of the former’s NerveTape, a sutureless peripheral nerve repair device.
Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.The strategic acquisition integrates NerveTape, the first FDA-approved sutureless nerve repair device, into Axogen’s existing surgical solutions for restoring peripheral nerve function.Funding The AcquisitionTo finance the $200 million purchase price, Axogen launched an underwritten public offering of 4.91 million shares of common stock, pri
This is the newest page. Registered accounts read further back.